Sarepta Therapeutics Shares Face Persistent Analyst Doubt Despite Upward Earnings Revision

Sarepta Therapeutics shares closed Friday’s trading session down 2.9 percent at $17.39, a decline that occurred despite a positive earnings forecast adjustment from Leerink Partners.

Mixed Signals from Research Firms

While Leerink Partners upgraded its third-quarter 2025 EPS estimate from -$1.08 to -$0.70, the firm maintained its “Hold” rating on the biopharmaceutical company. The broader analyst consensus, comprising seven research firms, also showed modest improvement, moving from -$0.37 to -$0.31 per share.

The overall sentiment toward Sarepta remains cautious. Among the 29 analyst firms covering the stock, recommendations include eight “Buy” ratings, fifteen “Hold” positions, and six “Sell” advisories. Price targets reflect significant divergence, ranging from $30.50 to $68.59 per share.

Regulatory Environment and Strategic Shifts

Significant regulatory developments in July 2025 created substantial uncertainty for the company. The FDA mandated a black box warning for ELEVIDYS following concerns about acute liver injury—a requirement to which Sarepta agreed. Prior to this decision, regulators had lifted a shipping suspension for the gene therapy product in ambulatory patients after an investigation could not attribute a reported death to the treatment.

Should investors sell immediately? Or is it worth buying Sarepta Therapeutics?

Concurrently, Sarepta initiated a major strategic overhaul, announcing a 36 percent reduction in its workforce as part of its future positioning. Market observers question whether these operational changes can effectively counterbalance the ongoing regulatory challenges.

Technical Indicators and Market Outlook

From a technical analysis perspective, Sarepta’s stock exhibits clear weakness, trading within what chartists describe as a “broad and declining trend.” Both short-term and long-term moving averages are generating sell signals, with the next critical support level identified at $16.75.

Investor attention now turns to quarterly results, scheduled for release in early November. These financials will provide crucial insight into the actual impact of recent developments and determine whether the prevailing conservative “Hold” stance among most analysts remains warranted.